Jeremy Skillington of Poolbeg: exclusive agreement with University College Dublin for a late preclinical stage vaccine candidate for Melioidosis
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Jeremy Skillington, CEO of Poolbeg Pharma #POLB outlines the exclusive Licence Agreement with University College Dublin for a late preclinical stage vaccine candidate for Melioidosis, a disease for which there is no currently approved vaccine available.
Highlights
The vaccine candidate, which is being developed by Poolbeg as POLB 003, was invented following many years of research by Associate Professor Siobhán McClean, UCD School of Biomolecular and Biomedical Science, and was a recipient of a Wellcome Trust Award to aid its development.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.